Impact BioMedical Inc. (IBO)
undefined
undefined%
At close: undefined

Company Description

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare.

It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.

The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.

In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications.

The company was incorporated in 2018 and is based in Houston, Texas.

Impact BioMedical Inc.
Impact BioMedical Inc. logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Frank D. Heuszel Esq., J.D.

Contact Details

Address:
1400 Broadfield Blvd.
Houston, Texas
United States
Website https://www.impactbiomedinc.com

Stock Details

Ticker Symbol IBO
Exchange AMEX
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001834105
CUSIP Number n/a
ISIN Number US45259L2051
Employer ID 85-3926944
SIC Code 2834

Key Executives

Name Position
Frank D. Heuszel Esq., J.D. Chairman & Chief Executive Officer
Mark J. Suseck Chief Operating Officer
Todd D. Macko CPA Chief Financial Officer. Secretary & Treasurer

Latest SEC Filings

Date Type Title
Dec 09, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Nov 22, 2024 4 Filing
Nov 12, 2024 10-Q Quarterly Report
Nov 04, 2024 8-K Current Report
Oct 08, 2024 8-K Current Report
Sep 19, 2024 4 Filing
Sep 18, 2024 4 Filing
Sep 18, 2024 3/A [Amend] Filing